Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01506570 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
A Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 3
- Study locations
NCT01506570: Completed Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01506570 is a Phase 1 study of Dengue that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 58 participants, below the 3,975-participant average among 9 other Dengue trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01506570, a Phase 1 study of Dengue, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 3
- Study locations
Study Summary
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses to two formulations of a tetravalent dengue virus vaccine in healthy adults who have previously been infected with a dengue virus or other flavivirus or have previously received a flavivirus vaccine.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL TetraVax-DV Vaccine - Admixture TV003
- BIOLOGICAL TetraVax-DV Vaccine - Admixture TV005
Study Locations (3)
Vermont
- Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC) - Burlington
- University of Vermont Vaccine Testing Center - Burlington
Maryland
- Center for Immunization Research, Johns Hopkins School of Public Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
What the finished NCT01506570 record still lists
NCT01506570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 3,975-participant average among 9 other Dengue trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01506570 reports a single indexed study location in Vermont, Maryland.
Frequently Asked Questions
What is clinical trial NCT01506570 about?
NCT01506570 is a clinical study titled "Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine". Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses to two formulations of a tetravalent dengue virus vaccine in healthy adults who have previously been...
What is the current status of trial NCT01506570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2011-12. Estimated completion is 2013-09.
What conditions does trial NCT01506570 study?
This clinical trial studies the following conditions: Dengue.
What interventions are being tested in trial NCT01506570?
The interventions under investigation include: Placebo (BIOLOGICAL), TetraVax-DV Vaccine - Admixture TV003 (BIOLOGICAL), TetraVax-DV Vaccine - Admixture TV005 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01506570?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01506570 being conducted?
This trial has 3 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01506570's enrollment target sits among peer trials
58 6th of 9 higher than 4 of 9 other Dengue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dengue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
COMPLETED · Phase 1
-
TDENV PIV and LAV Dengue Prime-boost Strategy
COMPLETED · Phase 1
-
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
COMPLETED · Phase 1
-
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
COMPLETED · Phase 1
-
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
COMPLETED · Phase 1
-
Tetravalent Chimeric Dengue Vaccine Trial
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia